Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.
Increased expression of CD30 is associated with a variety of hematologic malignancies, including Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL). The anti-CD30 monoclonal antibody SGN-30 induces direct antitumor activity by promoting growth arrest and DNA fragmentation of CD30(+) tumor cells. In this study, we investigated the contributions of Fc-mediated effector cell functions to SGN-30 activity. We determined that antibody-dependent cellular phagocytosis, mediated by macrophages, to contribute significantly to antitumor activity in vitro. To delineate the identity of the host effector cells involved in mediating antitumor activity in vivo, we studied the effects of effector cell ablation in a disseminated model of HD (L540cy). Depletion of macrophages markedly reduced efficacy of SGN-30, demonstrating that macrophages contribute significantly to SGN-30 efficacy in this model. These findings may have implications for patient stratification or combination treatment strategies in clinical trials conducted with SGN-30 in HD and ALCL.
Oflazoglu
Ezogelin
E
Department of Translational Biology, Seattle Genetics, WA 98021, USA.
Stone
Ivan J
IJ
Gordon
Kristine A
KA
Grewal
Iqbal S
IS
van Rooijen
Nico
N
Law
Che-Leung
CL
Gerber
Hans-Peter
HP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D045744:Cell Line, Tumor; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology; D008264:Macrophages / Q000276:immunology*; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D010587:Phagocytosis / Q000187:drug effects; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D017730:Ki-1 Antigen; C504717:SGN-30 monoclonal antibody